Part I: Parkin-associated proteins and Parkinson's disease

Neuropharmacology

Volumn 45, Issue 1, 2003, Pages 1-13

  Dev, Kumlesh K ^a   Van Der Putten, Herman ^a   Sommer, Bernd ^a   Rovelli, Giorgio ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Alzheimer's disease; Neurodegeneration; Parkin; Parkinson's disease; PDZ; Protein protein interactions; UbcH7 8; Ubiquitination

Indexed keywords

ALPHA SYNUCLEIN; CYTOCHALASIN D; G PROTEIN COUPLED RECEPTOR; GUANOSINE TRIPHOSPHATASE; HYDROLASE; NOCODAZOLE; PARKIN; PROTEIN; PROTEIN PAEL; SYNPHILIN 1; UBIQUITIN; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG;

ACTIN FILAMENT; BINDING AFFINITY; BRAIN REGION; CELL ACTIVITY; CELLULAR DISTRIBUTION; CLINICAL FEATURE; COMPLEX FORMATION; ENZYME ACTIVITY; ENZYME SUBSTRATE; GENE EXPRESSION; GENE FUNCTION; GENE STRUCTURE; HISTOPATHOLOGY; HUMAN; LEWY BODY; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REGULATORY MECHANISM; SHORT SURVEY; STRUCTURE ANALYSIS;

EID: 0038724238     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(02)00337-4     Document Type: Short Survey

References (103)

1. Abbas N., Lucking C.B., Ricard S., Durr A., Bonifati V., De Michele G., Bouley S., Vaughan J.R., Gasser T., Marconi R., Broussolle E., Brefel-Courbon C., Harhangi B.S., Oostra B.A., Fabrizio E., Bohme G.A., Pradier L., Wood N.W., Filla A., Meco G., Denefle P., Agid Y., Brice A. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. Human Molecular Genetics. 8:1999;567-574.
2. Adams M.D., et al. The genome sequence of Drosophila melanogaster. Science. 287:2000;2185-2195.
3. Alves-Rodrigues A., Gregori L., Figueiredo-Pereira M.E. Ubiquitin, cellular inclusions and their role in neurodegeneration. Trends in Neuroscience. 21:1998;516-520.
4. Ardley H.C., Tan N.G., Rose S.A., Markham A.F., Robinson P.A. Features of the parkin/ariadne-like ubiquitin ligase, HHARI, that regulate its interaction with the ubiquitin-conjugating enzyme, ubch7. Journal of Biological Chemistry. 276:2001;19640-19647.
5. Baba M., Nakajo S., Tu P.H., Tomita T., Nakaya K., Lee V.M., Trojanowski J.Q., Iwatsubo T. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. American Journal of Pathology. 152:1998;879-884.
6. Beal M.F. Energetics in the pathogenesis of neurodegenerative diseases. Trends in Neuroscience. 23:2000;298-304.
7. Beites C.L., Xie H., Bowser R., Trimble W.S. The septin CDCrel-1 binds syntaxin and inhibits exocytosis. Nature Neuroscience. 5:1999;434-439.
8. Bence N.F., Sampat R.M., Kopito R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science. 292:2001;1552-1555.
9. Bennett V., Chen L. Ankyrins and cellular targeting of diverse membrane proteins to physiological sites. Current Opinions in Cellular Biology. 13:2001;61-67.
10. Ben-Neriah Y. Regulatory functions of ubiquitination in the immune system. Nature Immunology. 3:2002;20-26.
11. Boddy M.N., et al. The p53-associated protein MDM2 contains a newly characterized zinc-binding domain called the RING finger. Trends in Biochemical Science. 19:1994;198-199.
12. Borden K.L. RING domains: master builders of molecular scaffolds? Journal of Molecular Biology. 295:2000;1103-1112.
13. Choi P., Ostrerova-Golts N., Sparkman D., Cochran E., Lee J.M., Wolozin B. Parkin is metabolized by the ubiquitin/proteosome system. Neuroreport. 11:2000;2635-2638.
14. Chung K.K., Zhang Y., Lim K.L., Tanaka Y., Huang H., Gao J., Ross C.A., Dawson V.L., Dawson T.M. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nature Medicine. 10:2001;1144-1150.
15. Cohen A.R., et al. Human CASK/LI N-2 binds syndecan-2 and protein 4.1 and iocalizes to the basoiaterai membrane of epithelial cells. Journal of Cellular Biology. 142:1998;129-138.
16. Cummings C.J., Mancini M.A., Antalffy B., DeFranco D.B., Orr H.T., Zoghbi H.Y. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nature Genetics. 19:1998;148-154.
17. Darios F., Corti O., Lucking C.B., Hampe C., Muriel M.P., Abbas N., Gu W.J., Hirsch E.C., Rooney T., Ruberg M., Brice A. Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Human Molecular Genetics. 12:2003;517-526.
18. Daw M.I., Chittajallu R., Bortolotto Z.A., Dev K.K., Duprat F., Henley J.M., Collingridge G.L., Isaac J.T. PDZ proteins interacting with C-terminal GluR2/3 are involved in a PKC-dependent regulation of AMPA receptors at hippocampal synapses. Neuron. 28:2000;873-886.
19. Dev K.K., Nishimure A., Henley J.M., Nakanishi S. The protein kinase C alpha binding protein PICK1 interacts with short but not long form alternative splice variants of AMPA receptor subunits. Neuropharmacology. 38:1999;635-644.
20. Dev K.K., Nakanishi S., Henley J.M. Regulation of mGlu7 receptors by proteins that interact with the intracellular C-terminus. Trends in Pharmacological Science. 22:2001;355-361.
21. Dev, K.K., Hofele, K., Barbieri, S., Buchman, V.L., van der Putten, H., 2003. Part II: α-synuclein and its molecular pathophysiological role in neurodegenerative disease. Neuropharmacology 45, this issue. PII: S0028-3908(03)00140-0.
22. Engelender S., Kaminsky Z., Guo X., Sharp A.H., Amaravi R.K., Kleiderlein J.J., Margolis R.L., Troncoso J.C., Lanahan A.A., Worley P.F., Dawson V.L., Dawson T.M., Ross C.A. Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nature Genetics. 22:1999;110-114.
23. Fallon L., Moreau F., Croft B.G., Labib N., Gu W.J., Fon E.A. Parkin and CASK/LIN-2 associate via a PDZ-mediated interaction and are co-localized in lipid rafts and postsynaptic densities in brain. Journal of Biological Chemistry. 277:2002;486-491.
24. Farrer M., Chan P., Chen R., Tan L., Lincoln S., Hernandez D., Forno L., Gwinn-Hardy K., Petrucelli L., Hussey J., Singleton A., Tanner C., Hardy J., Langston J.W. Lewy bodies and parkinsonism in families with parkin mutations. Annals in Neurology. 50:2001;293-300.
25. Feany M.B., Pallanck L.J. Parkin: a multipurpose neuroprotective agent? Neuron. 38:2003;13-16.
26. Field C.M., Kellogg D. Septins: cytoskeletal polymers or signalling GTPases? Trends in Cellular Biology. 9:1999;387-394.
27. Finney N., Walther F., Stauffer D., Rovelli G., Dev K.K. The expression level of parkin is regulated by its ubiquitin-like domain. Journal of Biological Chemistry. 278:2003;16054-16058.
28. Forno L.S. Neuropathology of Parkinson's disease. Journal of Neuropathology and Experimental Neurology. 55:1996;259-272.
29. Gasser T. Genetics of Parkinson's disease. Journal of Neurology. 248:2001;833-840.
30. Greene J.C., Whitworth A.J., Kuo I., Andrews L.A., Feany M.B., Pallanck L.J. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proceedings of the National Academy Science of the USA. 100:2003;4078-4083.
31. Gu W.J., et al. Cloning of rat parkin cDNA and distribution ofparkin in rat brain. Journal of Neurochemistry. 74:2000;1773-1776.
32. Handley P.M., Mueckler M., Siegel N.R., Ciechanover A., Schwartz A.L. Molecular cloning, sequence, and tissue distribution of the human ubiquitin-activating enzyme E1. Proceedings of the National Academy Science of the USA. 88:1991;258-262.
33. Hayashi S., Wakabayashi K., Ishikawa A., Nagai H., Saito M., Maruyama M., Takahashi T., Ozawa T., Tsuji S., Takahashi H. An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene. Movement Disorder. 15:2000;884-888.
34. Hershko A., Ciechanover A. The ubiquitin system. Annual Review of Biochemistry. 67:1998;425-479.
35. Hirbec H., Perestenko O., Nishimune A., Meyer G., Nakanishi S., Henley J.M., Dev K.K. The PDZ proteins PICK1, GRIP and Syntenin bind multiple glutamate receptor subtypes. Journal of Biological Chemistry. 277:2002;15221-15224.
36. Hornykiewicz, O., 1998. Biochemical aspects of Parkinson's disease. Neurology S2-9.
37. Huynh D.P., Scoles D.R., Ho T.H., Del Bigio M.R., Pulst S.M. Parkin is associated with actin filaments in neuronal and nonneural cells. Annals in Neurology. 48:2000;737-744.
38. Huynh D.P., Lee M.H., Hattori N., Kubo S.I., Mizuno Y., Halliwell B., Jenner P. Effect of wild type or mutant parkin on oxidative damage, nitric oxide, antioxidant defenses, and the proteasome. Journal of Biological Chemistry. 277:2002;28572-28577.
39. Imai Y., Soda M., Takahashi R. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. Journal of Biological Chemistry. 275:2000;35661-35664.
40. Imai Y., Soda M., Inoue H., Hattori N., Mizuno Y., Takahashi R. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell. 105:2001;891-902.
41. Imai Y., Soda M., Hatakeyama S., Akagi T., Hashikawa T., Nakayama K.I., Takahashi R. CHIP is associated with parkin, a gene responsible for Familial Parkinson's Disease and enhances its ubiquitin ligase activity. Molecular Cell. 10:2002;55-67.
42. Jenner P. Parkinson's disease, pesticides and mitochondrial dysfunction. Trends in Neuroscience. 24:2001;245-247.
43. Jensen P.H., Nielsen M.S., Jakes R., Dotti C.G., Goedert M. Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. Journal of Biological Chemistry. 273:1998;26292-26294.
44. Jo E., Fuller N., Rand R.P., St George-Hyslop P., Fraser P.E. Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein. Journal of Molecular Biology. 315:2002;799-807.
45. Joazeiro C.A., Wing S.S., Huang H., Leverson J.D., Hunter T., Liu Y.C. The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science. 286:1999;309-312.
46. Joazeiro C.A., Weissman A.M. RING finger proteins: mediators of ubiquitin ligase activity. Cell. 102:2000;549-552.
47. Kahle P.J., Leimer U., Haass C. Does failure of parkin-mediated ubiquitination cause juvenile parkinsonism? Trends in Biochemical Science. 25:2000;524-527.
48. Kartmann B., Roth D. Novel roles for mammalian septins: from vesicle trafficking to oncogenesis. Journal of Cellular Science. 114:2001;839-844.
49. Katada T.A., et al. Progress in the clinical and molecular genetics of familial parkinsonism. Progress in the clinical and molecular genetics of familial parkinsonism. Neurogenetics. 2:2000;207-218.
50. Katsanis N., Fisher E.M. Identification, expression, and chromosomal localization of ubiquitin conjugating enzyme 7 (UBE2G2), a human homologue of the saccharomyces cerevisiae UBC7 gene. Genomics. 51:1998;128-131.
51. Kimura M., Hattori T., Matsuda Y., Yoshioka T., Sumi N., Umeda Y., Nakashima S., Okano Y. cDNA cloning, characterization, and chromosome mapping of UBE2E2 encoding a human ubiquitin-conjugating E2 enzyme. Cytogenetics and Cellular Genetics. 78:1997;107-111.
52. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 392:1998;605-608.
53. Kitada T., Asakawa S., Matsumine H., Hattori N., Shimura H., Minoshima S., Shimizu N., Mizuno Y. Progress in the clinical and molecular genetics of familial parkinsonism. Neurogenetics. 2:2000;207-218.
54. Kitada T., et al. Molecuiar cloning, gene expression, and identification of a splicing variant of the mouse parkin gene. Mammal Genome. 11:2000;417-421.
55. Kopito R.R. Aggresomes, inclusion bodies and protein aggregation. Trends in Biochemical Science. 10:2000;524-530.
56. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schols L., Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nature Genetics. 18:1998;106-108.
57. Kubo S.I., Kitami T., Noda S., Shimura H., Uchiyama Y., Asakawa S., Minoshima S., Shimizu N., Mizuno Y., Hattori N. Parkin is associated with cellular vesicles. Journal of Neurochemistry. 78:2001;42-54.
58. Kumar S., Kao W.H., Howley P.M. Physical interaction between specific E2 and Hect E3 enzymes determines functional cooperativity. Journal of Biological Chemistry. 272:1997;13548-13554.
59. Lam Y.A., Pickart C.M., Alban A., Landon M., Jamieson C., Ramage R., Mayer R.J., Layfield R. Inhibition of the ubiquitin-proteasome system in Alzheimer's disease. Proceedings of the National Academy Science of the USA. 97:2000;9902-9906.
60. Langston J.W. Epidemiology versus genetics in Parkinson's disease: progress in resolving an age-old debate. Annals in Neurology. 44:1998;S45-52.
61. Lee F.J., Liu F., Pristupa Z.B., Niznik H.B. Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB Journal. 15:2001;916-926.
62. Leroy E., Boyer R., Auburger G., Leube B., Ulm G., Mezey E., Harta G., Brownstein M.J., Jonnalagada S., Chernova T., Dehejia A., Lavedan C., Gasser T., Steinbach P.J., Wilkinson K.D., Polymeropoulos M.H. The ubiquitin pathway in Parkinson's disease. Nature. 395:1998;451-452.
63. Li J., Uversky V.N., Fink A.L. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Biochemistry. 40:2001;11604-11613.
64. Lowe J., McDermott H., Landon M., Mayer R.J., Wilkinson K.D. Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases. Journal of Pathology. 161:1990;153-160.
65. Lucking C.B., Brice A. Alpha-synuclien and Parkinson's disease. Cellular and Molecular Life Science. 57:2000;1894-1908.
66. Lucking C.B., Durr A., Bonifati V., Vaughan J., De Michele G., Gasser T., Harhangi B.S., Pollak P., Bonnet A-M., Nichol D., Mari M.D., Marconi R., Broussolle E., Rascol O., Rosier M., Arnould I., Oostra B.A., Breteler M.M.B., Filla A., Meco G., Denefle P., Wood N.W., Agid Y., Brice A. Association between early-onset Parkinson's disease and mutations in the parkin gene. New England Journal of Medicine. 342:2000;1560-1567.
67. Mengesdorf T., Jensen P.H., Mies G., Aufenberg C., Paschen W. Down-regulation of parkin protein in transient focal cerebral ischemia: A link between stroke and degenerative disease? Proceedings of the National Academy Science of the USA. 99:2002;15042-15047.
68. Missier M., et al. The making of neurexins. Journal of Neurochemistry. 71:1998;1339-1347.
69. Mizuno Y., Hattori N., Matsumine H. Neurochemical and neurogenetic correlates of Parkinson's disease. Journal of Neurochemistry. 71:1998;893-902.
70. Morett E., Bork P. A novel transactivation domain in parkin. Trends in Biochemical Science. 24:1999;229-231.
71. Mori H., Kondo T., Yokochi M., Matsumine H., Nakagawa-Hattori Y., Miyake T., Suda K., Mizuno Y. Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology. 51:1998;890-892.
72. Moynihan T.P., Ardley H.C., Nuber U., Rose S.A., Jones P.F., Markham A.F., Scheffner M., Robinson P.A. The ubiquitin-conjugating enzymes UbcH7 and UbcH8 interact with RING finger/IBR motif-containing domains of HHARI and H7-AP1. Journal of Biological Chemistry. 274:1999;30963-30968.
73. Nishimune A., et al. Detection of protein-protein interactions in the nervous system using the two-hybrid system. Trends in Neuroscience. 19:1996;261-266.
74. Nuber U., et al. Cioning of human ubiquitin-conjugating enzymes UbcH6 and UbcH7 (E2-F1 ) and characterization of their interaction with E6-AP and RSP5. Journal of Biological Chemistry. 271:1996;2795-2800.
75. Pagano M. Cell cycle regulation by the ubiquitin pathway. FASEB Journal. 11:1997;1067-1075.
76. Peng X.R., Jia Z., Zhang Y., Ware J., Trimble W.S. The septin CDCrel-1 is dispensable for normal development and neurotransmitter release. Molecular and Cellular Biology. 22:2002;378-387.
77. Petrucelli L., O'Farrell C., Lockhart P.J., Baptista M., Kehoe K., Vink L., Choi P., Wolozin B., Farrer M., Hardy J., Cookson M.R. Parkin protects against the toxicity associated with mutant α-synuclein: proteasome dysfunction selectivity affects catecholaminergic neurons. Neuron. 36:2002;1007-1019.
78. Pickart C.M. Mechanisms underlying ubiquitination. Annual Review of Biochemistry. 70:2001;503-533.
79. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 276:1997;2045-2047.
80. Ponting C.P., Phillips C., Davies K.E., Blake D.J. PDZ domains: targeting signalling molecules to sub-membranous sites. Bioessays. 19:1997;469-479.
81. Ren Y., Zhao J., Feng J. Parkin binds to a α/β tubulin and increases their ubiquitination and degredation. Journal of Neuroscience. 23:2003;3316-3324.
82. Reyes J.C. PML and COP1 - two proteins with much in common. Trends in Biochemical Science. 26:2001;18-20.
83. Sakata E., Yamaguchi Y., Kurimoto E., Kikuchi J., Yokoyama S., Yamada S., Kawahara H., Yokosawa H., Hattori N., Mizuno Y., Tanaka K., Kato K. Parkin binds the Rpn10 subunit of 26S proteasomes through its ubiquitin-like domain. EMBO. Rep. 4:2003;301-306.
84. Schubert U., Anton L.C., Gibbs J., Norbury C.C., Yewdell J.W., Bennink J.R. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature. 404:2000;770-774.
85. Sheng M., Sala C. PDZ domains and the organization of supramolecular complexes. Annual Review in Neuroscience. 24:2001;1-29.
86. Shimura H., Hattori N., Kubo S., Yoshikawa M., Kitada T., Matsumine H., Asakawa S., Minoshima S., Yamamura Y., Shimizu N., Mizuno Y. Immunohistochemical and subcellular localization of parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients. Annals of Neurology. 45:1999;668-672.
87. Shimura H., Hattori N., Kubo S., Mizuno Y., Asakawa S., Minoshima S., Shimizu N., Iwai K., Chiba T., Tanaka K., Suzuki T. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nature Genetics. 25:2000;302-305.
88. Shimura H., Schlossmacher M.G., Hattori N., Frosch M.P., Trockenbacher A., Schneider R., Mizuno Y., Kosik K.S., Selkoe D.J. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science. 293:2001;263-269.
89. Songyang Z., Fanning A.S., Fu C., Xu J., Marfatia S.M., Chishti A.H., Crompton A., Chan A.C., Anderson J.M., Cantley L.C. Recognition of unique carboxyl-terminal motifs by distinct PDZ domains. Science. 275:1997;73-77.
90. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature. 388:1997;839-840.
91. Staropoli J.F., McDermott C., Martinat C., Schulman B., Demireva E., Abeliovich A. Parkin is a component of an SCF-like ubiquitin ligase complex and protects neurons from kainate excitotoxicity. Neuron. 37:2003;735-749.
92. Tanner C.M. The role of environmental toxins in the etiology of Parkinson's disease. Trends in Neuroscience. 12:1989;49-54.
93. Tofaris G.K., Layfield R., Spillantini M.G. Alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Letters. 509:2001;22-26.
94. Torres G.E., Yao W.D., Mohn A.R., Quan H., Kim K.M., Levey A.I., Staudinger J., Caron M.G. Functional interaction between monoamine plasma membrane transporters and the synaptic PDZ domain-containing protein PICK1. Neuron. 30:2001;121-134.
95. Ueda K., et al. Moiecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proceedings of the National Academy Science of the USA. 90:1993;11282-11286.
96. van Leuven F.W., Burbach J.P., Hol E.M. Mutations in RNA: a first example of molecular misreading in Alzheimer's disease. Trends in Neuroscience. 21:1998;331-335.
97. Voges D., Zwickl P., Baumeister W. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annual Review of Biochemistry. 68:1999;1015-1068.
98. Wakabayashi K., Engelender S., Yoshimoto M., Tsuji S., Ross C.A., Takahashi H. Synphilin-1 is present in Lewy bodies in Parkinson's disease. Annals in Neurology. 47:2000;521-523.
99. Ware J., Zieger B. Altemative expression of platelet glycoprotein Ib(beta) mRNA from an adjacent 5' gene with an imperfect polyadenylation signal sequence. Journal of Clinical Investigation. 99:1997;520-525.
100. Yang Y., Nishimura I., Imai Y., Takahashi R., Lu B. Parkin suppresses Dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron. 37:2003;911-924.
101. Zeng Z., et al. A novei endothelin receptor type-B-Iike gene enriched in the brain. Biochemistry and Biophysical Research Communications. 233:1997;559-567.
102. Zhang Y., Gao J., Chung K.K., Huang H., Dawson V.L., Dawson T.M. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proceedings of the National Academy Science of the USA. 97:2000;13354-13359.
103. Zheng N., Wang P., Jeffrey P.D., Pavletich N.P. Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases. Cell. 102:2000;533-539.